E-Peptides Control Bioavailability of IGF-1

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hede, Marianne Smedegaard ^a   Salimova, Ekaterina ^a,b   Piszczek, Agnieszka ^a   Perlas, Emarald ^a   Winn, Nadine ^a   Nastasi, Tommaso ^a   Rosenthal, Nadia ^a,b,c  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^b MONASH UNIVERSITY   (Australia)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GROWTH FACTOR 1 EA; INSULIN GROWTH FACTOR 1 EB; PEPTIDE E; RELAXIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SYSTEMIC CIRCULATION;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; BIOLOGICAL AVAILABILITY; BLOTTING, NORTHERN; DNA PRIMERS; EXTRACELLULAR MATRIX; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, TRANSGENIC; PEPTIDES; PROTEIN BINDING;

MURINAE; MUS MUSCULUS;

EID: 84870912911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051152     Document Type: Article

References (40)

1. Samani AA, Yakar S, LeRoith D, Brodt P, (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine reviews 28: 20-47.
2. Yakar S, Liu JL, Stannard B, Butler A, Accili D, et al. (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proceedings of the National Academy of Sciences of the United States of America. 96: 7324-7329.
3. Bell GI, Stempien MM, Fong NM, Rall LB, (1986) Sequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursors. Nucleic Acids Research 14: 7873-7882.
4. Simmons JG, Van Wyk JJ, Hoyt EC, Lund PK, (1993) Multiple transcription start sites in the rat insulin-like growth factor-I gene give rise to IGF-I mRNAs that encode different IGF-I precursors and are processed differently in vitro. Growth Factors 9: 205-221.
5. Dluzniewska J, Sarnowska A, Beresewicz M, Johnson I, Srai SK, et al. (2005) A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 19: 1896-1898.
6. Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, et al. (2008) Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart, lung & circulation 17: 33-39.
7. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V, (2011) Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of ageing and development 132: 154-162.
8. Pfeffer LA, Brisson BK, Lei H, Barton ER, (2009) The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Molecular biology of the cell 20: 3810-3817.
9. Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, et al. (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. The Journal of biological chemistry 270: 12109-12116.
10. Rabinovsky ED, Gelir E, Gelir S, Lui H, Kattash M, et al. (2003) Targeted expression of IGF-1 transgene to skeletal muscle accelerates muscle and motor neuron regeneration. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 17: 53-55.
11. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, et al. (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics 27: 195-200.
12. Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, et al. (2007) Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 21: 1393-1402.
13. Temmerman L, Slonimsky E, Rosenthal N, (2010) Class 2 IGF-1 isoforms are dispensable for viability, growth and maintenance of IGF-1 serum levels. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 20: 255-263.
14. Shavlakadze T, Boswell JM, Burt DW, Asante EA, Tomas FM, et al. (2006) Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy. Growth Horm IGF Res 16: 157-173.
15. Santini MP, Winn N, Rosenthal N (2006) Signalling pathways in cardiac regeneration. Novartis Found Symp 274: 228-238; discussion 239-243, 272-226.
16. Semenova E, Koegel H, Hasse S, Klatte JE, Slonimsky E, et al. (2008) Overexpression of mIGF-1 in keratinocytes improves wound healing and accelerates hair follicle formation and cycling in mice. The American journal of pathology 173: 1295-1310.
17. Bach MA, Roberts CT Jr, Smith EP, LeRoith D, (1990) Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Molecular endocrinology 4: 899-904.
18. Wilson HE, Westwood M, White A, Clayton PE, (2001) Monoclonal antibodies to the carboxy-terminal Ea sequence of pro-insulin-like growth factor-IA (proIGF-IA) recognize proIGF-IA secreted by IM9 B-lymphocytes. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 11: 10-17.
19. Shavlakadze T, Winn N, Rosenthal N, Grounds MD, (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 15: 4-18.
20. Bosman FT, Stamenkovic I, (2003) Functional structure and composition of the extracellular matrix. The Journal of pathology 200: 423-428.
21. Cox MND, editor (2004) Lehninger, Principles of Biochemistry: Freeman.
22. Gallagher JT, (2001) Heparan sulfate: growth control with a restricted sequence menu. The Journal of clinical investigation 108: 357-361.
23. Gillies AR, Smith LR, Lieber RL, Varghese S, (2011) Method for decellularizing skeletal muscle without detergents or proteolytic enzymes. Tissue engineering Part C, Methods 17: 383-389.
24. Arai T, Busby W Jr, Clemmons DR, (1996) Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137: 4571-4575.
25. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR, (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 121: 679-687.
26. Taipale J, Keski-Oja J, (1997) Growth factors in the extracellular matrix. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 11: 51-59.
27. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, et al. (2008) Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nature Medicine 14: 213-221.
28. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, et al. (2010) Regeneration and orthotopic transplantation of a bioartificial lung. Nature Medicine 16: 927-933.
29. Machingal MA, Corona BT, Walters TJ, Kesireddy V, Koval CN, et al. (2011) A tissue-engineered muscle repair construct for functional restoration of an irrecoverable muscle injury in a murine model. Tissue engineering Part A 17: 2291-2303.
30. Yu SR, Burkhardt M, Nowak M, Ries J, Petrasek Z, et al. (2009) Fgf8 morphogen gradient forms by a source-sink mechanism with freely diffusing molecules. Nature 461: 533-536.
31. Flintegaard TV, Thygesen P, Rahbek-Nielsen H, Levery SB, Kristensen C, et al. (2010) N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology 151: 5326-5336.
32. Ates K, Yang SY, Orrell RW, Sinanan AC, Simons P, et al. (2007) The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Letters 581: 2727-2732.
33. Yang SY, Goldspink G, (2002) Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Letters 522: 156-160.
34. Winn N, Paul A, Musaro A, Rosenthal N, (2002) Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. Cold Spring Harbor symposia on quantitative biology 67: 507-518.
35. Barton ER, DeMeo J, Lei H, (2010) The insulin-like growth factor (IGF)-I E-peptides are required for isoform-specific gene expression and muscle hypertrophy after local IGF-I production. Journal of Applied Physiology 108: 1069-1076.
36. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. The Journal of Cell Biology 168: 193-199.
37. Schertzer JD, van der Poel C, Shavlakadze T, Grounds MD, Lynch GS, (2008) Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 294: C161-168.
38. Casellas A, Salavert A, Agudo J, Ayuso E, Jimenez V, et al. (2006) Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. Diabetes 55: 3246-3255.
39. Rosenthal N, Kornhauser JM, Donoghue M, Rosen KM, Merlie JP, (1989) Myosin light chain enhancer activates muscle-specific, developmentally regulated gene expression in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 86: 7780-7784.
40. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N, (1999) IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581-585.